Mobile

A randomized, double-blind phase II trial to assess the efficacy and safety of bicalutamide (Casodex® ) associated to ZD6474 (Zactima™ ) or to placebo in patients with castration-refractory metastatic...

Mise à jour : Il y a 4 ans
Référence : EUCTR2007-001891-35

A randomized, double-blind phase II trial to assess the efficacy and safety of bicalutamide (Casodex® ) associated to ZD6474 (Zactima™ ) or to placebo in patients with castration-refractory metastatic prostate cancer without any clinical symptom related to disease progression

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To assess the effect of ZD6474 (Vandetanib, Zactima™ ) on time to prostate specific antigen (PSA) progression (TTP) in patients with castration-refractory metastatic prostate cancer, without any clinical symptom related to disease progression.

Critère d'inclusion

  • metastatic prostate cancer

Liens